Discovering significant breakthroughs in fibrosis.


Blade is founded on a commitment to revolutionize the treatment of debilitating fibrotic diseases.

Fibrosis is a complex, pathologic process characterized by the thickening or scarring of organ tissue in response to cell/tissue damage or inflammation. Once afflicted, the tissue no longer functions normally. Fibrosis may overwhelm organs that include the liver, lung, skin, kidney, joints and eye. Fibrotic diseases are incurable, impairing the lives of millions of people worldwide.

While the underlying pathophysiology of fibrosis is complex, research continues to enhance our understanding of the disease processes. At Blade, we are experts in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell and tissue damage responses leading to fibrosis.

Autotaxin / LPA and calpains each play distinct roles within the biological pathways underlying fibrosis. Ongoing dysregulation of those pathways underlies the progression and severity of fibrosis and resulting organ dysfunction.

Autotaxin in fibrosis

Pro-fibrotic processes are stimulated by autotaxin, a key enzyme that plays a complementary role to calpains in various fibrotic diseases.

Autotaxin regulates the production of lysophosphatidic acid (LPA) that can become over-activated in response to aberrant signaling or cell damage. Both autotaxin and LPA are produced in response to inflammation to mediate wound repair (cicatrization). View the graphic below for a step-by-step explanation.

The autotaxin / LPA axis impacts development of disease, with aberrant LPA signaling linked to broad range of pathophysiological conditions. Increased autotaxin levels and activity are associated with liver, lung, kidney and skin fibrosis. Inhibition of the autotaxin / LPA receptor pathway has been clinically validated in idiopathic pulmonary fibrosis (IPF) and in scleroderma. In addition, autotaxin levels correlate with fibrosis severity in various liver diseases (NAFLD / NASH, viral hepatitis, ALD, cirrhosis).


Stoddard, 2015, Biomol Ther. 23(1):1.

Matralis, 2019, Med Res Rev. 39(3):976.

Maher, 2018, Lancet Resp Med. 6(8):627.

Palmer, 2018, Chest. 154(5):1061.

Galapagos company news release. 10 Sept 2020.